Mr Andrew Bowskill

MTPConnect, Australia’s MedTech and Pharma Growth Centre

Presented by Mr Andrew Bowskill

Overview

MTPConnect was formed in 2015 as part of the Federal Government’s Industry Growth Centre Initiative. It is a not-for-profit organisation aiming to accelerate the rate of growth of the medtech, biotech and pharmaceuticals sector in Australia. MTPConnect raises awareness, fosters collaboration and competition, aggregates existing knowledge and shares it with the broader sector. It also jointly funds projects that address the Sector Growth Priorities and the constraints and gaps identified in the sector.

MTPConnect has recently launched it’s Queensland Hub, located at the TRI, and appointed a State Director of Stakeholder Engagement, in recognition of Queensland’s strong medical research community and its significance to the Australian medtech, biotech and pharmaceutical sector.

About Mr Andrew Bowskill

Andrew Bowskill is the Director of Stakeholder Engagement for Queensland at the Translational Research Institute (TRI). Prior to this he was Manager of Industry and Regulatory Policy at Medicines Australia, where he engaged with a broad cross section of stakeholders including consumer groups, companies, peak bodies and Commonwealth and State officials. Andrew has a deep understanding of MTP industry and regulatory policy including R&D policy, intellectual property, trade agreements and biosimilars.

Andrew has a Bachelor of Pharmacy from the University of Otago and has held a number of pharmacy roles in Queensland including Clinical Pharmacist, Adult Emergency and Medical Admissions and Planning Unit, Mater Pharmacy Services and Team Leader, Mater Private Hospital Pharmacy.